阿扎胞苷联合DAG方案治疗急性髓系白血病的临床研究

Clinical study of azacytidine combined with DAG regimen on acute myeloid leukemia

目的探讨阿扎胞苷联合DAG方案(柔红霉素+阿糖胞苷+重组人粒细胞集落刺激因子)治疗急性髓系白血病(AML)患者的临床效果。方法回顾性分析2020年9月至2021年12月收治的200例AML患者临床资料。根据治疗方案不同分为对照组(DAG方案,100例)与观察组(阿扎胞苷联合DAG方案,100例)。以21 d为1个疗程,需治疗2个疗程。对比2组患者临床疗效、细胞免疫功能及治疗期间药物毒副反应。结果观察组临床总有效率高于对照组(P<0.05);治疗后,2组CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+) 值均低于治疗前(P<0.05),但治疗后,组间细胞免疫细胞指标比较,差异无统计学意义(P>0.05)。治疗期间,对比2组药物毒副反应率,差异无统计学意义(P>0.05)。结论阿扎胞苷联合DAG方案治疗可提高AML患者临床疗效,且不加重患者免疫抑制状态及药物毒副作用。

Objective To investigate the clinical effect of azacytidine combined with DAG regimen(daunorubicin+cytarabine+recombinant human granulocyte colony stimulating factor)on patients with acute myeloid leukemia(AML).Methods T The clinical data of 200 AML patients admitted to our hospital from September 2020 to December 2021 were retrospectively analyzed.The patients were randomly assigned in a 1∶1 ratio to receive either DAG scheme(control group)or azacytidine+DAG scheme(observation group)for two treating courses(21 days as a course).The clinical efficacy,cellular immune function and drug toxicity of patients in the two groups during treatment were compared.Results After treatment,the total effective rate in the observation group was significantly higher than that in the control group(P<0.05).The values of CD_(3)^(+),CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+) in both groups were significantly lower than those before treatment(P<0.05).However,there was no statistically significant difference in cellular immune indexes between groups(P>0.05).There was no statistical significant difference in drug toxicity between groups during the treatment(P>0.05).Conclusion For AML patients,azacytidine combined with DAG regimen can improve the clinical efficacy without aggravating the immunosuppressive state and drug side effects.